Eligible AACR 2019 Annual Meeting Registrants – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

The Next Generation of Clinical Trials in Molecularly Driven Therapy

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 7 of 7
Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi)
David Hyman
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
from AACR Annual Meeting 2019 on April 1, 2019 3:00 PM-5:00 PM
Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive metastatic breast cancer with prior chemotherapy for advanced disease (TBCRC 035): A Phase II study with pharmacodynamic markers
Hope S Rugo
University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, United States
from AACR Annual Meeting 2019 on April 1, 2019 3:00 PM-5:00 PM
Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN study
Shibu Thomas
Janssen Research & Development, Spring House, PA, United States
from AACR Annual Meeting 2019 on April 1, 2019 3:00 PM-5:00 PM
Molecular-biological tumor profiling for drug treatment selection in patients with advanced and refractory carcinoma: A prospective, two-stage Phase II individualized cancer treatment study
Samantha O Perakis
Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria
from AACR Annual Meeting 2019 on April 1, 2019 3:00 PM-5:00 PM
Entrectinib in NTRK-fusion positive (NTRK-FP) non-small cell lung cancer (NSCLC): Integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1 and ALKA-372-001)
Robert Doebele
University of Colorado, Aurora, CO, United States
from AACR Annual Meeting 2019 on April 1, 2019 3:00 PM-5:00 PM
Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open-label, registration directed Phase II study
Nathan H Fowler
MD Anderson Cancer Center, Houston, TX, United States
from AACR Annual Meeting 2019 on April 1, 2019 3:00 PM-5:00 PM
Interim results of a Phase I/II trial of intratumoral CpG, local low-dose radiation, and oral ibrutinib in patients with low-grade B-cell lymphoma
Tanaya Shree
Stanford University, Stanford, CA, United States
from AACR Annual Meeting 2019 on April 1, 2019 3:00 PM-5:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 7 of 7